Late-stage opportunity Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, presenting a potential near-term market entry and high-value collaboration or licensing opportunities for specialty distributors and payer partnerships.

Delivery tech leverage The company emphasizes innovative drug delivery technologies like PharmFilm, offering potential sales pathways to partner with biologics or small molecules that require novel administration routes, enabling co-development or licensing discussions with pharma companies seeking patient-friendly formats.

Licensed product footprint Avec four licensed commercialized products marketed through partners, Aquestive maintains an established manufacturing and supply chain role, presenting opportunities to expand demand by securing new licensees or expanding production capacity for existing licensed portfolios.

Financial momentum Recent positive quarterly revenue signals and a substantial debt refinancing raise liquidity and financial visibility, creating openings for strategic collaborations, co-development funding, or structured financing deals with potential risk-sharing for new programs.

Regulatory risk signals The wave of securities-related litigation activity noted in 2026 poses compliance and reputational risk considerations for partners; proactive due diligence and clear governance frameworks should be emphasized in any BD outreach to build trust and reduce deal friction.